Original Source(s)
Related Content
FDA expands gastroesophageal cancer options
Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.
August 25, 2026
-
2 min
Autism Spectrum Disorder Linked to Distinct Urine Metabolite Pattern
Researchers proposed a new autism spectrum disorder phenotype characterized by elevated urinary microbially derived metabolites.
July 14, 2026
-
5 min
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min
